CMLD010509

Request For Quotation
CMLD010509 Suppliers list
Company Name: Fan De(Beijing) Biotechnology Co., Ltd.  
Tel: 15911056312
Email: liming@bio-fount.com
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: Beijing Biocreative Technology Co., Ltd.  
Tel: 15522676233
Email: 3007606172@qq.com
Company Name: Nantong QuanYi Biotechnology Co., Ltd  
Tel: 0513-66337626 18051384581
Email: sales@chemhifuture.com
Company Name: RD International Technology Co., Limited  
Tel: 18024082417
Email: market@ubiochem.com

CMLD010509 manufacturers

  • CMLD010509
  • CMLD010509 pictures
  • $2500.00
  • 2026-07-16
  • CAS:256497-58-2
  • Purity:
  • Supply Ability: 10g
  • CMLD010509
  • CMLD010509 pictures
  • $2500.00
  • 2026-07-15
  • CAS:256497-58-2
  • Purity:
  • Supply Ability: 10g
  • CMLD010509
  • CMLD010509 pictures
  • $2500.00
  • 2025-08-22
  • CAS:256497-58-2
  • Purity:
  • Supply Ability: 10g
CMLD010509 Basic information
Product Name:CMLD010509
Synonyms:CMLD010509;SDS-1-021;CMLD-010509,CMLD010509;1H-Cyclopenta[b]benzofuran-2-carboxamide, 3a-(4-bromophenyl)-2,3,3a,8b-tetrahydro-1,8b-dihydroxy-N,6,8-trimethoxy-3-phenyl-, (1R,2R,3S,3aR,8bS)-rel-
CAS:256497-58-2
MF:C27H26BrNO7
MW:556.4
EINECS:
Product Categories:
Mol File:256497-58-2.mol
CMLD010509 Structure
CMLD010509 Chemical Properties
density 1.519±0.06 g/cm3(Predicted)
pka11.56±0.70(Predicted)
form Solid
color White to off-white
Safety Information
MSDS Information
CMLD010509 Usage And Synthesis
DescriptionCMLD010509 is a highly specific inhibitor of the oncogenic translation program supporting multiple myeloma (MM)-including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1.
UsesCMLD010509 (SDS-1-021) is a highly specific inhibitor of the oncogenic translation program supporting multiple myeloma (MM)-including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1. CMLD010509 (SDS-1-021) shows an IC50 below 10 nM for most MM cell lines and induces apoptosis. CMLD010509 (SDS-1-021) is a potent and selective translation inhibitor through an eIF4E phosphorylation-independent mechanism[1].
References[1] Manier S, et al. Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Sci Transl Med. 2017 May 10;9(389). pii: eaal2668. DOI:10.1126/scitranslmed.aal2668
CMLD010509 Preparation Products And Raw materials
Tag:CMLD010509(256497-58-2) Related Product Information
CMLD010509 1H-Cyclopenta[b]benzofuran-2-carboxamide, 2,3,3a,8b-tetrahydro-1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-3-phenyl-, (1R,2R,3S,3aR,8bS)- 1H-Cyclopenta[b]benzofuran-2-carboxamide, 2,3,3a,8b-tetrahydro-1,8b-dihydroxy-N,6,8-trimethoxy-3a-(4-methoxyphenyl)-3-phenyl-, (1S,2S,3R,3aS,8bR)- 1H-Cyclopenta[b]benzofuran-2-carboxamide, 2,3,3a,8b-tetrahydro-1,8b-dihydroxy-N,6,8-trimethoxy-3a-(4-methoxyphenyl)-N-methyl-3-phenyl-, (1R,2R,3S,3aR,8bS)- 1H-Cyclopenta[b]benzofuran-2-carboxamide, 2,3,3a,8b-tetrahydro-1,8b-dihydroxy-N,6,8-trimethoxy-3a-(4-methoxyphenyl)-3-phenyl-, (1R,2R,3S,3aR,8bS)- 1H-Cyclopenta[b]benzofuran-2-carboxamide, 2,3,3a,8b-tetrahydro-1,8b-dihydroxy-3a-(4-hydroxyphenyl)-6,8-dimethoxy-3-phenyl-, (1R,2R,3S,3aR,8bS)-